Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» hemophilia A
hemophilia A
Could This Drug Candidate Be a Blockbuster for Sanofi?
Motley Fool
Sun, 04/10/22 - 07:43 pm
Sanofi
efanesoctocog alfa
hemophilia A
Sanofi, scarred by Roche scrap, hits goal in once-weekly hemophilia A trial and plots race to regulators
Fierce Biotech
Wed, 03/9/22 - 10:54 am
Sanofi
Roche
Sobi
hemophilia A
clinical trials
BioMarin's hemophilia A gene therapy hits goal in phase 3, teeing up FDA filing despite durability doubts
Fierce Biotech
Mon, 01/10/22 - 11:32 am
Biomarin
hemophilia A
gene therapy
valrox
clinical trials
Sigilon Uncovers Possible Reason Behind Hemophilia A Trial Hold
BioSpace
Tue, 11/30/21 - 10:28 am
Siglion Therapeutics
cell therapy
FDA
hemophilia A
SIG-001
Genentech Hemophilia A Drug Displays Long-term Safety, Efficacy
BioSpace
Mon, 07/19/21 - 11:09 pm
Genentech
Hemlibra
hemophilia A
clinical trials
BioMarin (BMRN) Hemophilia Gene Therapy Gets FDA's RMAT Tag
Yahoo/Zacks.com
Tue, 03/9/21 - 10:37 am
Biomarin
gene therapy
hemophilia A
valoctocogene roxaparvovec
FDA
RMAT
Sanofi revises fitusiran dosing to cut risk of thrombotic events in hemophilia phase 3
Fierce Biotech
Mon, 02/8/21 - 10:41 am
Sanofi
fitusiran
hemophilia
hemophilia A
hemophila B
Gene therapy for hemophilia: So close, yet so far away
BioPharma Dive
Thu, 01/28/21 - 11:18 pm
hemophilia
hemophilia A
hemophilia B
gene therapy
Biomarin
uniQure
BioMarin tries to get hemophilia gene therapy back on track with positive data
BioPharma Dive
Mon, 01/11/21 - 10:40 am
Biomarin
hemophilia A
gene therapy
clinical trials
Roctavian
#ASH20 Best of the Rest: Pfizer, Sangamo launch a durability charge at BioMarin in hem A; The data behind Merck's $4.5B buyout
Endpoints
Mon, 12/7/20 - 10:32 am
ASH2020
uniQure
hemophilia A
Sangamao
gene therapy
Biomarin
How BioMarin Beat Expectations in Q3
Motley Fool
Fri, 11/6/20 - 09:55 am
Biomarin
hemophilia A
earnings
Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment SB-525
Drugs.com
Wed, 10/7/20 - 11:33 pm
Pfizer
Sangamo Therapeutics
genomics
clinical trials
hemophilia A
giroctocogene fitelparvovec
SB-525
Sanofi's hemophilia drug comes into focus as delays hit a key competitor
BioPharma Dive
Thu, 09/10/20 - 11:19 pm
Sanofi
hemophilia
hemophilia A
BIVV001
Is valrox dead?
EP Vantage
Thu, 08/20/20 - 11:09 am
Biomarin
hemophilia A
valrox
gene therapy
Roche
Pfizer
FDA
FDA gets out its red pen again, rejecting BioMarin's gene therapy valrox amid durability worries
Fierce Biotech
Wed, 08/19/20 - 09:28 am
Biomarin
FDA
valrox
hemophilia A
Roche targets 2021 start for hemophilia A gene therapy phase 3 as optimization effort drags on
Fierce Biotech
Mon, 07/13/20 - 11:11 am
Roche
hemophilia A
Spark Therapeutics
SPK-8011
Pfizer, Sangamo flesh out hemophilia gene therapy data ahead of phase 3
Fierce Biotech
Thu, 06/18/20 - 10:38 am
Pfizer
Sangamo BioSciences
hemophilia A
clinical trials
gene therapy
giroctocogene fitelparvovec
BioMarin Shares Additional Promising Phase I/II Data on Hemophilia A Treatment
BioSpace
Wed, 06/17/20 - 10:00 pm
Biomarin
clinical trials
hemophilia A
valoctocogene roxaparvovec
BioMarin gene therapy shows sustained benefit in hemophilia A study
Seeking Alpha
Mon, 06/1/20 - 10:42 am
Biomarin
hemophilia A
clinical trials
gene therapy
valoctocogene roxaparvovec
Regeneron to expand development deal with Intellia Therapeutics
Marketwatch
Mon, 06/1/20 - 10:30 am
Regeneron
Intellia Therapeutics
hemophilia A
hemophilia B
CRISPR
drug development
Pages
« first
‹ previous
1
2
3
4
5
next ›
last »